- ￥1668
- abinScience
- China
- VK521053
- 2025年07月25日
- ELISA
- Alpaca
- Nipah virus (NiV)
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Alpaca
- 亚型：
VHH-His
- 形态：
Liquid
- 保存条件：
0.01M PBS, pH 7.4.
- 克隆性：
Monoclonal
- 标记物：
Unconjugated
- 适应物种：
Nipah virus (NiV)
- 保质期：
1 year
- 抗原来源：
Alpaca
- 目录编号：
VK521053
- 级别：
科研级别
- 库存：
999
- 供应商：
abinScience
- 宿主：
Alpaca
- 应用范围：
ELISA
- 浓度：
1mg/mL
- 靶点：
Fusion glycoprotein, Protein F, Fusion glycoprotein F
- 抗体英文名：
Anti-Nipah virus/NiV Fusion glycoprotein Nanobody (DS90)
- 抗体名：
Anti-Nipah virus/NiV Fusion glycoprotein Nanobody (DS90)
- 规格：
100ul
| Product name | Anti-Nipah virus/NiV Fusion glycoprotein Nanobody (DS90) |
|---|---|
| Catalog No. | VK521053 |
| Host species | Alpaca |
| Species reactivity | Nipah virus (NiV) |
| Immunogen | / |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Purity | >90% as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Isotype | VHH-His |
| Applications | ELISA |
| Target | Fusion glycoprotein, Protein F, Fusion glycoprotein F |
| Purification | Purified by Nickel column. |
| Endotoxin level | Please contact with the lab for this information. |
| Expression system | / |
| Accession | Q9IH63 |
| Alternative Names | / |
| Clone ID | DS90 |
| Species | / |
| Product Usage Information | / |
abinScience, founded in 2023 in Strasbourg, France, is committed to developing and producing high-quality life science reagents. Rooted in one of Europe’s leading hubs for scientific innovation, abinScience empowers global research through reliable, efficient experimental solutions. Guided by the vision of “Empowering Bioscience Discovery,” we support scientists worldwide in advancing the frontiers of bioscience.
Technology and Innovation
Relying on the global leading position in antibody and protein research and more than 20 years of industry experience of its parent company ProteoGenix since 2003, abinScience has inherited advanced technologies and high-quality standards. In particular, the XtenCHO™ system developed by ProteoGenix, which has two modes of transient expression and stable expression, has been widely recognized as a core technology to improve the efficiency of protein production, providing a solid foundation for abinScience's product research and development.
Product categories and application fields.
Main products.
10000+ high-activity proteins.
15000+ antibody series products:
Classic monoclonal antibody.
Monoclonal antibody
Internal control antibody, labeled antibody.
High-quality phosphorylation antibodies.
Highly specific nanobodies and small molecule antibodies.
Functional antibodies in vivo.
Low-background flow cytometry antibodies.
DNA/RNA antibodies and PEG antibodies.
1000+ reagent kit series products.
Large-scale packaging customization services: We offer personalized antibody design, protein production, molecular optimization, and experimental development services.
Application field
Infectious disease research: including viruses, superbugs, parasites, etc.
Neuroscience research: Supporting research on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Immunology research: Covers the research needs of immune activation, inhibition, and allergies and abnormal reactions.
Oncology research: Supporting the development of tumor biology and anti-tumor drugs.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验• Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus., PMID:24179220
• Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine., PMID:37023209
• The Hantavirus Surface Glycoprotein Lattice and Its Fusion Control Mechanism., PMID:32937107
• Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV., PMID:27478931
• Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies., PMID:35985336
• A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein., PMID:31515478
• Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus., PMID:37738240
• Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model., PMID:34702618
• Molecular Evolution of Attachment Glycoprotein (G) and Fusion Protein (F) Genes of Respiratory Syncytial Virus ON1 and BA9 Strains in Xiamen, China., PMID:35311585
Viral Glycoprotein-Mediated Cell Fusion Assays Using Vaccinia Virus Vectors
The vaccinia virus-based expression of viral envelope glycoprotein genes—derived from enveloped viruses that infect their respective host cells through a pH-independent mechanism of membrane fusion—has been a powerful tool in helping
Characterization of HIV gp120 Envelope Glycoprotein by Lectin Analysis
The envelope glycoprotein gp120 of the human immunodeficiency virus (HIV), the causative agent of AIDS, contains approx 24 potential sites for N -glycosylation (Asn-X-Ser/Thr, X≠Pro) (1 ), all of which are utilized
Expression, Glycosylation, and Modification of the Spike (S) Glycoprotein of SARS CoV
syndrome (SARS)-coronavirus (CoV) within the host cell, a T7/vaccinia virus-based expression system coupled to immunoprecipitation with anti-S antibodies was used to test and analyze different forms of the S glycoprotein. The state of maturity of the S
技术资料暂无技术资料 索取技术资料
